Urocit®-K at a dosage of 60 mEq/day will:
Treatment with extended-release potassium citrate should be added to a regimen that limits salt intake (avoidance of foods with high salt content and of added salt at the table) and encourages high fluid intake (urine volume should be at least 2 liters per day). Urocit-K 15 mEq (1620 mg) should be taken with meals or within 30 minutes after meals or bedtime snacks.
*Remission defined as “the percentage of patients remaining free of newly formed stones during treatment.” Group I: n=19 (10 renal tubular acidosis, 9 chronic diarrheal syndrome). Group II: n=37 (5 uric acid stones alone, 6 uric acid lithiasis and calcium stones, 3 type I absorptive hypercalciuria, 9 type II absorptive hypercalciuria and 14 hypocitraturia). Group III: n=15 (history of relapse on other therapy). Group IV: n=18 (9 type I absorptive hypercalciuria and calcium stones, 1 type II absorptive hypercalciuria and calcium stones, 2 hyperuricosuria calcium oxalate nephrolithiasis, 4 uric acid lithiasis accompanied by calcium stones and 2 hypocitraturia and hyperuricemia accompanied by calcium stones).
Prescribe maximum-strength Urocit-K 15 mEq for patients who may: